Jane Street
IMDX

Jane Street’s Insight Molecular Diagnostics IMDX Stock Holding History

Jane Street’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-42,469
Closed -$319K – 12579
2025
Q4 		$319K Buy
+42,469
New +$240K ﹤0.01% 8702
2023
Q2 		– Sell
-1,240
Closed -$8.79K – 9300
2023
Q1 		$8.79K Sell
1,240
-863
-41% -$6.41K ﹤0.01% 8750
2022
Q4 		$13.5K Buy
2,103
+567
+37% +$6.25K ﹤0.01% 8693
2022
Q3 		$22K Buy
+1,536
New +$26.6K ﹤0.01% 9180
2021
Q2 		– Sell
-1,775
Closed -$184K – 10213
2021
Q1 		$184K Buy
+1,775
New +$169K ﹤0.01% 8326
2020
Q4 		– Sell
-920
Closed -$26K – 7922
2020
Q3 		$26K Sell
920
-1,648
-64% -$47.3K ﹤0.01% 7009
2020
Q2 		$98K Buy
+2,568
New +$133K ﹤0.01% 6713
2019
Q3 		– Sell
-3,567
Closed -$178K – 5541
2019
Q2 		$178K Buy
3,567
+2,969
+496% +$247K ﹤0.01% 4719
2019
Q1 		$47K Buy
+598
New +$38.6K ﹤0.01% 4837

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jane Street's IMDX Position: Q1 2026 in Review

Jane Street sold out of Insight Molecular Diagnostics (IMDX) in Q1 2026, closing a stake of 42,469 shares — an estimated $319K sold.

Jane Street first reported a position in IMDX in Q1 2019 and held it in 9 quarters. The position peaked at $319K in Q4 2025. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Jane Street reported no remaining Insight Molecular Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 42,469 Insight Molecular Diagnostics shares in Q1 2026, an estimated $319K.
  • Jane Street first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 9 quarters.
  • Jane Street's Insight Molecular Diagnostics position peaked at $319K in Q4 2025.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.